RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000083.xml
Synlett 2008(17): 2617-2620
DOI: 10.1055/s-0028-1083511
DOI: 10.1055/s-0028-1083511
LETTER
© Georg Thieme Verlag
Stuttgart ˙ New York
Formal Synthesis of Leustroducsin B
Weitere Informationen
Received
2 July 2008
Publikationsdatum:
01. Oktober 2008 (online)
Publikationsverlauf
Publikationsdatum:
01. Oktober 2008 (online)
Abstract
A formal synthesis of leustroducsin B, a potent antitumor compound, is described featuring two key reactions: an olefin cross-metathesis between α-methylene γ-butyrolactone and a terminal olefin to install the C7-C12 carbon backbone, and a highly stereoselective Brown-type pentenylation which sets the syn-relationship between the two substituents at C4 and C5.
Key words
leustroducsins - antitumor - asymmetric pentenylation - ring-closing metathesis - Sharpless dihydroxylation
-
1a
Kohama T.Enokita R.Okazaki T.Miyaoka H.Torikata A.Inukai M.Kaneko I.Kagasaki T.Sakaida Y.Satoh A.Shiraishi A. J. Antibiot. 1993, 46: 1503 -
1b
Kohama T.Nakamura T.Kinoshita T.Kaneko I.Shiraishi A. J. Antibiot. 1993, 46: 1512 -
1c
Matsuhashi H.Shimada K. Tetrahedron 2002, 58: 5619 -
2a
Fushimi S.Nishikawa S.Shimazu A.Seto H. J. Antibiot. 1989, 42: 1019 -
2b
Fushimi S.Furihata K.Seto H. J. Antibiot. 1989, 42: 1026 -
2c
Ozasa T.Suzuki K.Sasamata M.Tanaka K.Kobori M.Kadota S.Nagai K.Saito T.Watanabe S.Iwanami M. J. Antibiot. 1989, 42: 1331 -
2d
Ozasa T.Tanaka K.Sasamata M.Kaniwa H.Shimizu M.Matsumoto H.Iwanami M. J. Antibiot. 1989, 42: 1339 -
2e
Shibata T.Kurihara S.Yoda K.Haruyama H. Tetrahedron 1995, 51: 11999 -
2f
Sekiyama Y.Palaniappan N.Reynolds KA.Osada H. Tetrahedron 2003, 59: 7465 -
2g
Choudhuri SD.Ayers S.Soine WH.Reynolds KA. J. Antibiot. 2005, 58: 573 -
2h
Mizuhara N.Usuki Y.Ogita M.Fujita K.Kuroda M.Doe M.Lio H.Tanaka T. J. Antibiot. 2007, 60: 762 -
2i
Nonaka H.Maeda N.Kobayashi Y. Tetrahedron Lett. 2007, 48: 5601 ; and references therein -
3a
Lewy DS.Gauss CM.Soenen DR.Boger DL. Curr. Med. Chem. 2002, 9: 2005 -
3b
Uramoto M.Shen YC.Takizawa N.Kusakabe H.Isono K. J. Antibiot. 1985, 38: 665 - 4
Kawada M.Kawatsu M.Masuda T.Ohba S.Amemiya M.Kohama T.Ishizuka M.Takeuchi T. Int. Immunopharmacol. 2003, 3: 179 - 5
Koishi R.Yoshimura C.Kohama T.Serizawa N.
J. Interferon Cytokine Res. 2002, 22: 343 - 6
Shimada K.Kaburagi Y.Fukuyama T. J. Am. Chem. Soc. 2003, 125: 4048 -
7a
Miyashita K.Tsunemi T.Hosokawa T.Ikejiri M.Imanishi T. Tetrahedron Lett. 2007, 48: 3829 -
7b
Miyashita K.Tsunemi T.Hosokawa T.Ikejiri M.Imanishi T. J. Org. Chem. 2008, 73: 5360 - 8 Hatakeyama et al. have very recently
disclosed a similar procedure in their synthesis of phoslactomycin
B, see:
Shibahara S.Fujino M.Tashiro Y.Takahashi K.Ishihara J.Hatakeyama S. Org. Lett. 2008, 10: 2139 -
9a
Pospísil J.Markó IE. Tetrahedron Lett. 2006, 47: 5933 -
9b
Enders D.Lenzen A.Müller M. Synthesis 2004, 1486 - 10
Moïse J.Arseniyadis S.Cossy J. Org. Lett. 2007, 9: 1695 - 11
Brown HC.Bhat KS. J. Am. Chem. Soc. 1986, 108: 293 - 13
Stork G.Zhao K. Tetrahedron Lett. 1989, 30: 2173
References and Notes
The second diastereomer could not be detected by either ¹H or ¹³C NMR spectroscopy of the crude reaction mixture, thus suggesting a selectivity superior to 95:5.